As in the previous years, EANpages asked EAN committee members, panel chairs, and invited speakers which session one should not miss at the upcoming congress in Oslo 2019. Please find their answers below!
Antonella Macerollo, Member of the EAN e-Communication Committee
Liverpool, United Kingdom
Cannabinoids: between neuroinflammation and neurodegeneration, Saturday, 29 June 2019 from 8:30-10:00
I will not miss this session because the role of endocannabinoids in Neurology has becoming an emerging topic and there is still an ongoing debate about the involvement in the pathophysiology of several diseases as well as her potential benefit in the treatment of neurodegenerative and neuroinflammatory neurological disorders. Attending this workshop will give me the possibility to learn the practical rationale, the beneficial and deleterious effects of cannabinoid-based medication use in neurology, for both already known and emerging indications. All these new knowledges are essential in my current clinical practice.
Miguel Tábuas Pereira, Member of the EAN Education Committee
Biomarkers in degenerative dementia: news and views from the European Dementia with Lewy Body (DLB) Consortium, Friday, 29 June 2019 from 10:30-12:30
Dementia, as a whole, is one of the most prevalent neurological disorders and Lewy body dementia is considered to be the second most prevalent type. In a pre-treatment age, reliable biomarkers are essential, namely preclinical biomarkers, as we have learnt that we have to treat dementia before the actual clinical process. Currently, Lewy body dementia is probably the degenerative dementia where preclinical (non-genetic) biomarkers are more diverse. It is a fastly developing area, important not only for neurologist who are interested in dementia or movement disorders, but to all neurologists, as in the future, dementia diagnosis will probably be performed many years before cognitive impairment.
Bo Norrving, Invited Speaker at the EAN Congress
Management of stroke in young adults, Monday, 1 July 2019 from 8:00-9:30
There has been significant progress in the understanding of stroke in the young during the last few years. Many “black areas” have been enlightened, but many enigmas still exist. It is like solving a detective story, which is not fiction but real. I’ll take this opportunity to update my knowledge where the field stands now. I know these speakers will deliver, all being world class experts. I suggest you come and join me here!
Prof. Dr. Johann Sellner, FAAN, FANA, FEAN, Member of the EAN Education Committee, Management Committee Neuroinfection Panel and Speaker at the congress
Dilemmas in Neuroinflammatory Disease in the ICU, Saturday, 29 June 2019 from 8:30-10:00
I am looking forward to this session which will provide practical insights to major challenges for diagnosis and treatment of aggressive manifestations of autoimmune CNS disorders
Claudia Sommer, Chair of the EAN Teaching Course sub-Committee
Future treatments of neuroinflammation and neuroimmune diseases, Saturday, 29 June 2019 from 8:30
This focused workshop is not only part of the overarching theme, it also promises to help me understand which neuroimmune disorders will respond to B-cell therapies, which ones to T-cell therapies, and how and when inflammation is good or bad for brain repair.